Luo Anqi, Wu Fang, Han Rui, Huang Shangke, Zhang Yujiao, Jing Xin, Zhao Xinhan
Department of Medical Oncology, School of Medicine, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, P.R. China.
J Cancer Res Ther. 2017;13(5):778-784. doi: 10.4103/jcrt.JCRT_543_17.
Bone metastases (BMs) are common for breast cancer patients. However, triple-negative breast cancer (TNBC) with BM is relatively rare and few data on it are available. In this study, we aim to investigate the incidence and clinicopathological features and to evaluate the prognosis of TNBC patients with BM.
A total of 616 patients with TNBC (120 out of them had BM) between 2007 and 2011 were involved in the study. Clinicopathological characteristics were statistically analyzed.
A total of 120 (19.5%) patients developed BM with a median age of 53.1 years. The median overall survival (OS) was 40 months, and the 5-year OS rate was 37.3% in TNBC patients with BM. Patients without BM had longer survival time than those with BM (P < 0.001). In the univariate analysis, lymph nodes metastasis, tumor Stage III-IV, multiple BMs, and coexistence of visceral metastasis were correlated to a poor prognosis (P = 0.020; P < 0.001; P < 0.001; P < 0.001). Moreover, multivariate analysis demonstrated that tumor stage, number of BM, and visceral metastasis were significantly independent factors for OS (P < 0.001; P < 0.001; P < 0.001).
Tumor Stage III-IV, multiple BMs, or coexistence of visceral metastasis were associated with poor prognosis for OS in TNBC patients with BM. These associations may contribute to prevention, early detection, and goal-directed treatment of bone metastatic TNBC.
骨转移(BMs)在乳腺癌患者中很常见。然而,发生骨转移的三阴性乳腺癌(TNBC)相对少见,相关数据也较少。在本研究中,我们旨在调查TNBC骨转移患者的发病率、临床病理特征并评估其预后。
本研究纳入了2007年至2011年间共616例TNBC患者(其中120例发生骨转移)。对临床病理特征进行了统计学分析。
共有120例(19.5%)患者发生骨转移,中位年龄为53.1岁。TNBC骨转移患者的中位总生存期(OS)为40个月,5年总生存率为37.3%。未发生骨转移的患者生存期长于发生骨转移的患者(P < 0.001)。单因素分析显示,淋巴结转移、肿瘤Ⅲ - Ⅳ期、多发骨转移和内脏转移并存与预后不良相关(P = 0.020;P < 0.001;P < 0.001;P < 0.001)。此外,多因素分析表明,肿瘤分期、骨转移数量和内脏转移是OS的显著独立影响因素(P < 0.001;P < 0.001;P < 0.001)。
肿瘤Ⅲ - Ⅳ期、多发骨转移或内脏转移并存与TNBC骨转移患者的OS预后不良相关。这些关联可能有助于骨转移性TNBC的预防、早期检测和针对性治疗。